Rise and shine, another busy day is on the way. However, this is also shaping up as a beautiful day as well, given the clear and sunny skies — and delicious breezes — enveloping the Pharmalot campus this morning.
This calls for celebration with a cup of stimulation, and we are opening a new package of cinnamon buns for the occasion. Spring has sprung, after all.
What is upon us right now, however, is our ever-growing to-do list. Sound familiar?
So here are some items of interest. Have a great day, everyone.
… U.S. Health and Human Services Secretary Robert F.
Kennedy Jr. announced several initiatives intended to rein in the prescription of selective serotonin reuptake inhibitors, the most widely prescribed class of antidepressants, which he has described as exceptionally difficult to quit , The New York Times writes.
The initiative focuses on the most widely prescribed class of psychiatric medications, first-line treatments for depression and anxiety that include Zoloft, Lexapro, Paxil, and Prozac. In 2026.
16.7% of U.S.
STAT News published a clinical update in Research Highlights on 05 May 2026.
The item focuses on STAT+: Pharmalittle: We’re reading about RFK Jr.
targeting antidepressants, J&J pushing an IBD drug, and more.
Review the original article for the full source wording and details.